News

The digital platform Science4Pandemics, in which we are a partner, has launched two new citizen science projects for adolescents between the ages of 12 and 17,

This year’s edition of our innovative training course “PentaTr@ining: HIV & other Congenital Infections” finally drew to a close at the end of September, and we are delighted to report…

Quantitative and qualitative data have a mutually beneficial relationship. Quantitative data need the depth of qualitative evidence to be adequately interpreted, and qualitative evidence benefits from being based on robust…

The People First Charter was launched on 20th July 2021 to promote person-first language in the field of HIV. We are proud to endorse this much-needed charter which will ensure…

On September 19, 2022, we kicked off our exciting new online course, “Fungal Infections in Paediatrics” on our PentaTr@ining platform, with over 100 delegates logging in from across the world.

The position of Senior Clinical Research Fellow is now available at the MRC CTU. The position is open to clinicians with experience in the management of infectious diseases, in particular…

Babies and young children treated with the anti-HIV drug dolutegravir, in combination with other anti-HIV drugs, are more likely to keep the virus under control, compared to those treated with…

We are happy to announce that registrations are now open for our new interactive training course ‘Fungal Infections in Paediatrics‘! Building on the combined expertise within the European Paediatric Mycology…

CARMA Global is an EPIICAL cross-sectional, multi-country, multi-site, low interventional study on children, adolescents and youth who started ART at three months or younger at least seven years ago and…

We are proud to endorse the International Workshop on HIV and adolescents taking place from 5-6 October 2022, in Cape Town, South Africa. The workshop brings together experts from across…

The PentaTr@ining Zambia-Tanzania 2022 course was held on 18-20 July. It was Penta’s first-ever jointly hosted training course in Africa and it counted more than 200 participants with nearly 150…

Results from a substudy of the ODYSSEY trial show that children being treated for tuberculosis (TB) and HIV at the same time can safely have the anti-HIV medicine dolutegravir twice…

The second VERDI General Assembly took place from 28-30 June 2022, bringing together more than 70 people both online and in Padua, Italy. This hybrid meeting spotlighted the important work…

The methodology team at the MRC Clinical Trials Unit at UCL is a key partner of Penta and has made a huge contribution to our studies on HIV.

A large study on the effectiveness of the Pfizer-BioNTech’s Covid-19 vaccine in children aged 5-11 was published in The New England Journal of Medicine. The study was conducted at Israel’s…

Between 13th-15th June 2022, around 140 beneficiaries of the c4c consortium met in Ghent Belgium for the c4c General Assembly. This was the first time since 2019 that the consortium…

A new trial opened in May, aiming to find out if children and young people living with HIV can take two anti-HIV medicines instead of three. The trial has already…

The first two participants of the SHIELD trial (PENTA-22) were screened by Dr. Renate Strehlau and her team at Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa in June 2022.